Biotech Values

[oc631]

I think the risk of a bear market for stocks in general was a bigger factor in the timing of MNTA’s financing than concerns about Teva’s Lovenox.

Under the sole generic agreement MNTA has incredible cash flow for a company it's size. The market timing spin doesn't work for me.